Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Patients With Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03310008
What this trial is testing

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

Who this might be right for
Colon Cancer Liver Metastasis
Celyad Oncology SA 36
Not applicableEnded earlyNCT00151476
What this trial is testing

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Who this might be right for
Familial Adenomatous Polyposis (FAP)
Pfizer 68
Early research (Phase 1)Looking for participantsNCT04881240
What this trial is testing

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, RefractoryPediatric ALL
St. Jude Children's Research Hospital 60
Testing effectiveness (Phase 2)UnknownNCT01807468
What this trial is testing

Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors

Who this might be right for
NeuroblastomaEwing SarcomaRhabdomyosarcoma+2 more
Samsung Medical Center 12
Testing effectiveness (Phase 2)Ended earlyNCT03827850
What this trial is testing

FGFR Inhibitor in FGFR Dysregulated Cancer

Who this might be right for
Lung CancerNSCLCPulmonary Neoplasm+2 more
Lung Cancer Group Cologne 22
Testing effectiveness (Phase 2)Study completedNCT00585650
What this trial is testing

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

Who this might be right for
Psoriasis
University of California, Irvine 20
Very early researchLooking for participantsNCT04005690
What this trial is testing

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Who this might be right for
Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute 90
Not applicableUnknownNCT02145013
What this trial is testing

Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma

Who this might be right for
Primary Liver Cancers
Henri Mondor University Hospital 200
Large-scale testing (Phase 3)Study completedNCT00008060
What this trial is testing

Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Medical Research Council
Testing effectiveness (Phase 2)Study completedNCT04997382
What this trial is testing

Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 112
Not applicableLooking for participantsNCT05502224
What this trial is testing

Multidisciplinary Approach to Fatigue

Who this might be right for
Breast CancerGerm Cell Tumor
Jules Bordet Institute 50
Testing effectiveness (Phase 2)Ended earlyNCT02489123
What this trial is testing

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Ann Arbor Stage I Mantle Cell LymphomaAnn Arbor Stage II Mantle Cell LymphomaAnn Arbor Stage III Mantle Cell Lymphoma+3 more
University of Washington 8
Not applicableStudy completedNCT02296580
What this trial is testing

A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)

Who this might be right for
Glioblastoma Multiforme
Nativis, Inc. 37
Testing effectiveness (Phase 2)Study completedNCT00004923
What this trial is testing

Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Yale University 47
Testing effectiveness (Phase 2)Looking for participantsNCT06712680
What this trial is testing

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

Who this might be right for
Solid Tumor
Sichuan Huiyu Pharmaceutical Co., Ltd 115
Testing effectiveness (Phase 2)UnknownNCT03693326
What this trial is testing

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Who this might be right for
CancerLung Cancer MetastaticImmunotherapy
Asan Medical Center 70
Large-scale testing (Phase 3)UnknownNCT06545526
What this trial is testing

Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis

Who this might be right for
Familial Adenomatous Polyposis
Yonsei University 28
Large-scale testing (Phase 3)UnknownNCT00657878
What this trial is testing

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Who this might be right for
Ovarian Cancer
National Cancer Institute, Naples 215
Testing effectiveness (Phase 2)Active Not RecruitingNCT03179943
What this trial is testing

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Fox Chase Cancer Center 21
Large-scale testing (Phase 3)Study completedNCT02766335
What this trial is testing

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Who this might be right for
Recurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7
SWOG Cancer Research Network 116
Next Page